Home Newsfeeds ‘Instagram Scaling Back Shopping Features Amid Commerce Retreat’ – The Information

News

‘Instagram Scaling Back Shopping Features Amid Commerce Retreat’ – The Information

https://www.theinformation.com/articles/instagram-scaling-back-shopping-features-amid-commerce-retreat

byBenzinga Newsdesk

September 6, 2022

1 minute read

https://www.theinformation.com/articles/instagram-scaling-back-shopping-features-amid-commerce-retreat

News

CBAK Energy Enters Partnership Agreement With Welson Power For Indian Market

By Bill Haddad

August 19, 8:30 AM

CBAK Energy Technology, Inc. (NASDAQ:CBAT) ("CBAK Energy," or the "Company"), a leading lithium-ion battery manufacturer and electric energy solution provider in China, today announced that its wholly

CBAT

Why Matson Shares Are Surging Today?

By Shivani Kumaresan

July 21, 12:09 PM

Matson Inc (NYSE:MATX) shares are surging today after the company announced strong preliminary second-quarter FY23 results. The company expects Q2 2023 net…

MATX

Jim Carmer Is ‘A Seller’ Of This Company Because ‘Elon Musk Said That He Doesn’t Like That Business’

By Priya Nigam

October 11, 8:51 AM

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Abbott Laboratories (NYSE: ABT) is a "very good company and will be up to the—let’s say—up to the challenge. I think that’s fair.

ABT

News

Marinus Pharmaceuticals Wraps Phase 3 Trial Enrollment for Tuberous Sclerosis Complex Treatment, Targets New Drug Application in 2025 Following Phase 3 Seizure Treatment Trial

By Benzinga Newsdesk

May 17, 7:02 AM

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced completion of enrollment in the global Phase 3

MRNS

‘Instagram Scaling Back Shopping Features Amid Commerce Retreat’ – The Information

Related Posts

CBAK Energy Enters Partnership Agreement With Welson Power For Indian Market

Why Matson Shares Are Surging Today?

Jim Carmer Is ‘A Seller’ Of This Company Because ‘Elon Musk Said That He Doesn’t Like That Business’

Marinus Pharmaceuticals Wraps Phase 3 Trial Enrollment for Tuberous Sclerosis Complex Treatment, Targets New Drug Application in 2025 Following Phase 3 Seizure Treatment Trial